Novel therapies for peripheral T-cell non-Hodgkin's lymphomas

Purpose of review To review new agents under investigation for the treatment of patients with peripheral T-cell lymphoma. Recent findings New agents being evaluated in these patients include histone deacetylase inhibitors (e.g. romidepsin, vorinostat, and balinostat), purine analogs and agents that interfere with the purine metabolic pathway (e.g. forodesine), immunomodulatory agents, proapoptotic small molecules (e.g. oblimersen, obatoclax, and gossypol), antifols (e.g. pralatrexate), proteasome inhibitors (e.g. bortezomib), monoclonal antibodies against T-cell antigens (e.g. CD30 and CD52), and immunotoxins (e.g. denileukin diftitox). Summary The development of rational combinations of such agents in clinical trials will be required to improve the outcome of these patients.